Pedro Sánchez‐Godoy

673 total citations
18 papers, 220 citations indexed

About

Pedro Sánchez‐Godoy is a scholar working on Genetics, Pathology and Forensic Medicine and Oncology. According to data from OpenAlex, Pedro Sánchez‐Godoy has authored 18 papers receiving a total of 220 indexed citations (citations by other indexed papers that have themselves been cited), including 10 papers in Genetics, 7 papers in Pathology and Forensic Medicine and 7 papers in Oncology. Recurrent topics in Pedro Sánchez‐Godoy's work include Chronic Lymphocytic Leukemia Research (10 papers), Lymphoma Diagnosis and Treatment (7 papers) and Viral-associated cancers and disorders (5 papers). Pedro Sánchez‐Godoy is often cited by papers focused on Chronic Lymphocytic Leukemia Research (10 papers), Lymphoma Diagnosis and Treatment (7 papers) and Viral-associated cancers and disorders (5 papers). Pedro Sánchez‐Godoy collaborates with scholars based in Spain, United States and Japan. Pedro Sánchez‐Godoy's co-authors include Carlos Montalbán, Juan F. Garcı́a, Miguel Á. Piris, Rafael Martínez, Miguel Méndez, Manuel M. Morente, Eulogio Conde, Víctor Abraira, Carlos Grande and José Belló and has published in prestigious journals such as Journal of Clinical Oncology, Blood and PLoS ONE.

In The Last Decade

Pedro Sánchez‐Godoy

17 papers receiving 215 citations

Peers

Pedro Sánchez‐Godoy

PFM

ONCOL

HEMAT

GENET

Fernando Solano Spain

Hein P. J. Visser Netherlands

Christine Moung United States

Bertrand Nadel France

Kaiyang Ding China

Miki Kiyota Japan

Machiko Tsukaguchi Japan

Ryan J. Stubbins Canada

Helen Marr United Kingdom

Stephen K. H. Li Canada

Fernando Solano Spain

Pedro Sánchez‐Godoy

122 ×1.2

PFM

92 ×0.9

63 ×1.0

ONCOL

56 ×1.2

HEMAT

103 ×2.2

GENET

Citations per year, relative to Pedro Sánchez‐Godoy Pedro Sánchez‐Godoy (= 1×) peers Fernando Solano

Countries citing papers authored by Pedro Sánchez‐Godoy

Since Specialization

Citations

This map shows the geographic impact of Pedro Sánchez‐Godoy's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Pedro Sánchez‐Godoy with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Pedro Sánchez‐Godoy more than expected).

Fields of papers citing papers by Pedro Sánchez‐Godoy

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Pedro Sánchez‐Godoy. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Pedro Sánchez‐Godoy. The network helps show where Pedro Sánchez‐Godoy may publish in the future.

Co-authorship network of co-authors of Pedro Sánchez‐Godoy

This figure shows the co-authorship network connecting the top 25 collaborators of Pedro Sánchez‐Godoy. A scholar is included among the top collaborators of Pedro Sánchez‐Godoy based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Pedro Sánchez‐Godoy. Pedro Sánchez‐Godoy is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

18 of 18 papers shown

Martínez‐López, Joaquín, Javier de la Cruz, José‐Ángel Hernández‐Rivas, et al.. (2022). COVID-19 Severity and Survival over Time in Vaccinated Patients with Hematologic Malignancies. Blood. 140(Supplement 1). 7924–7925.

Sánchez‐Godoy, Pedro, et al.. (2020). Increase in Mortality and Second Neoplasms in Chronic Lymphocytic Leukemia with Pro/Pro Genotype of TP53 Codon 72. Blood. 136(Supplement 1). 13–14. 1 indexed citations

Alonso‐Domínguez, Juan Manuel, Luis Felipe Casado, Eduardo Anguita, et al.. (2017). PTCH1 is a reliable marker for predicting imatinib response in chronic myeloid leukemia patients in chronic phase. PLoS ONE. 12(7). e0181366–e0181366. 6 indexed citations

García-Vela, José A., Natalia Gómez‐Lozano, Margarita Sánchez‐Beato, et al.. (2016). BiallelicATMalterations detected at diagnosis identify a subset of treatment-naïve chronic lymphocytic leukemia patients with reduced overall survival similar to patients with p53 deletion. Leukemia & lymphoma. 58(4). 859–865. 6 indexed citations

Navarro, Belén, Isabel Millán, Rosa Collado, et al.. (2014). Vascular Endothelial Growth Factor A (VEGFA) Gene Polymorphisms Have an Impact on Survival in a Subgroup of Indolent Patients with Chronic Lymphocytic Leukemia. PLoS ONE. 9(6). e101063–e101063. 9 indexed citations

Martínez‐López, Joaquín, Ramón García‐Sánz, François Pépin, et al.. (2013). Prognostic value of deep sequencing method for minimal residual disease (MRD) detection in multiple myeloma.. Journal of Clinical Oncology. 31(15_suppl). 8511–8511. 2 indexed citations

Sánchez‐Espiridión, Beatriz, Ana M. Martín‐Moreno, Carlos Montalbán, et al.. (2013). MicroRNA signatures and treatment response in patients with advanced classical Hodgkin lymphoma. British Journal of Haematology. 162(3). 336–347. 36 indexed citations

Barragán, Eva, Pau Montesinos, Mireia Camós, et al.. (2011). Prognostic value of FLT3 mutations in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and anthracycline monochemotherapy. Haematologica. 96(10). 1470–1477. 39 indexed citations

Vallejo, Carlos, Eduardo Ríos, Javier de la Serna, et al.. (2011). Incidence of cytomegalovirus infection and disease in patients with lymphoproliferative disorders treated with alemtuzumab. Expert Review of Hematology. 4(1). 9–16. 15 indexed citations

10.

Tomás, José Francisco, Carlos Montalbán, Alberto Fernández de Sevilla, et al.. (2011). Frontline treatment of follicular lymphoma with fludarabine, cyclophosphamide, and rituximab followed by rituximab maintenance: toxicities overcome its high antilymphoma effect. Results from a Spanish Cooperative Trial (LNHF-03). Leukemia & lymphoma. 52(3). 409–416. 5 indexed citations

11.

Rivero, Ana, Inmaculada Rapado, José Francisco Tomás, et al.. (2010). Relationship between deoxycytidine kinase (DCK) genotypic variants and fludarabine toxicity in patients with follicular lymphoma. Leukemia Research. 35(4). 431–437. 4 indexed citations

12.

Sánchez‐Espiridión, Beatriz, Abel Sánchez‐Aguilera, Carlos Montalbán, et al.. (2009). A TaqMan Low-Density Array to Predict Outcome in Advanced Hodgkin's Lymphoma Using Paraffin-Embedded Samples. Clinical Cancer Research. 15(4). 1367–1375. 27 indexed citations

13.

Martínez‐López, Joaquín, Ana Rivero, Inmaculada Rapado, et al.. (2009). Influence ofMBL-2mutations in the infection risk of patients with follicular lymphoma treated with rituximab, fludarabine, and cyclophosphamide. Leukemia & lymphoma. 50(8). 1283–1289. 4 indexed citations

14.

García-Vela, José A., E. Ruı́z, Rafael Forés, et al.. (2007). Alemtuzumab as a Single Agent or Combined with Methylprednisolone (MPD) or Fludarabine (FDR) for the Treatment of CLL Patients with p53 and ATM Deletions.. Blood. 110(11). 3121–3121. 1 indexed citations

15.

Serrano, David, Pascual Balsalobre, Rafael Carrión, et al.. (2006). Comparative Study of Autologous Stem Cell Transplant (ASCT) in HIV-1 Positive (HIV+) on Haart and HIV-1 Negative (HIV−) Non Hodgkin Lymphoma (NHL) Patients.. Blood. 108(11). 3063–3063. 4 indexed citations

16.

Montalbán, Carlos, Juan F. Garcı́a, Víctor Abraira, et al.. (2004). Influence of Biologic Markers on the Outcome of Hodgkin's Lymphoma: A Study by the Spanish Hodgkin’s Lymphoma Study Group. Journal of Clinical Oncology. 22(9). 1664–1673. 54 indexed citations

17.

Cuétara, María Soledad, et al.. (2000). [Erythematous nodule in a hematology patient].. PubMed. 18(6). 287–8. 1 indexed citations

18.

Montalbán, Carlos, Ana Isabel Manzanal Martínez, D Boixeda, et al.. (1998). [Treatment of low-grade gastric MALT lymphoma with Helicobacter pylori eradication. Follow-up of the histological and molecular response].. PubMed. 110(2). 41–4. 6 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact